Clinical Development in the Nordic Region & Northern Europe

1st-2nd December, 2008, Hotel Scandic Copenhagen, Denmark
The Nordic and Northern European region is still widely regarded as a very attractive location to run clinical studies. Such countries are internationally regarded for their exceptionally high-quality healthcare systems, which are well funded, with a strong infrastructure, highly trained medical personnel and a rich academic tradition. However like other Western European countries, clinical site saturation is becoming an important issue in this region as the number of studies increase, as well as their complexity. Nordic and Northern European countries must maintain their competitive edge in contrast to other emerging clinical regions with larger, treatment naive patient populations. This event will bring together the regions clinical Key Opinion Leaders to discuss and share what is now required, specifically: fresh perspectives, innovative ideas and new approaches.

This conference offers a rare opportunity for the clinical trial industry in Nordic and Northern European countries to come together, understand and develop a best-practice approach to site selection and increasing patient recruitment performance. It will be a unique chance for pharma, biotech, medical device and other clinical trial sponsors, CROs, principal investigators, ethics committees and regulatory drug agencies to benchmark, share experiences, network and drive forward partnerships. All participants will walk away with a greater understanding of how to take advantage of this dynamic region, whether running studies in-house or through clinical outsourcing partnerships.

For further information and registration, please visit:
http://www.nextlevelpharma.com

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...